Ampligen rintatolimod: Phase I/II started

Hemispherx said investigators began an open-label, U.S. Phase I/II trial to evaluate 4, 20, 79 and 495 µg intradermal Ampligen plus the university's vaccine consisting of synthetic peptide derived fro...